全文获取类型
收费全文 | 5521篇 |
免费 | 421篇 |
国内免费 | 149篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 183篇 |
妇产科学 | 78篇 |
基础医学 | 634篇 |
口腔科学 | 202篇 |
临床医学 | 664篇 |
内科学 | 1165篇 |
皮肤病学 | 69篇 |
神经病学 | 521篇 |
特种医学 | 430篇 |
外科学 | 431篇 |
综合类 | 147篇 |
一般理论 | 3篇 |
预防医学 | 624篇 |
眼科学 | 70篇 |
药学 | 526篇 |
1篇 | |
肿瘤学 | 330篇 |
出版年
2022年 | 38篇 |
2021年 | 70篇 |
2020年 | 43篇 |
2019年 | 73篇 |
2018年 | 86篇 |
2017年 | 57篇 |
2016年 | 68篇 |
2015年 | 74篇 |
2014年 | 109篇 |
2013年 | 172篇 |
2012年 | 257篇 |
2011年 | 237篇 |
2010年 | 154篇 |
2009年 | 176篇 |
2008年 | 242篇 |
2007年 | 301篇 |
2006年 | 186篇 |
2005年 | 219篇 |
2004年 | 174篇 |
2003年 | 166篇 |
2002年 | 215篇 |
2001年 | 159篇 |
2000年 | 174篇 |
1999年 | 143篇 |
1998年 | 126篇 |
1997年 | 115篇 |
1996年 | 112篇 |
1995年 | 98篇 |
1994年 | 72篇 |
1993年 | 85篇 |
1992年 | 114篇 |
1991年 | 107篇 |
1990年 | 115篇 |
1989年 | 128篇 |
1988年 | 117篇 |
1987年 | 105篇 |
1986年 | 119篇 |
1985年 | 99篇 |
1984年 | 78篇 |
1983年 | 66篇 |
1982年 | 71篇 |
1981年 | 51篇 |
1980年 | 45篇 |
1979年 | 60篇 |
1978年 | 50篇 |
1977年 | 48篇 |
1976年 | 58篇 |
1974年 | 41篇 |
1970年 | 42篇 |
1968年 | 41篇 |
排序方式: 共有6091条查询结果,搜索用时 15 毫秒
81.
Influence of glucose kinetics on plasma lactate concentration and energy expenditure in severely burned patients 总被引:5,自引:0,他引:5
Gore DC Ferrando A Barnett J Wolf SE Desai M Herndon DN Goodwin C Wolfe RR 《The Journal of trauma》2000,49(4):673-7; discussion 677-8
BACKGROUND: In critically ill patients, elevation in the plasma lactate concentration has traditionally been interpreted as indicating a deficiency in oxygen availability and is often an impetus to increase oxygen delivery clinically. However, another possible basis for increased lactate concentrations may be simply a mass effect from increased pyruvate availability (i.e., accelerated glycolysis). METHODS: In six hypermetabolic burned patients, the rates of glucose production and oxidation were quantified using a tracer infusion of 6,6 d2 glucose combined with indirect calorimetry. Measurements were obtained after a 9-hour fast and after a 3-hour infusion of unlabeled glucose at 30 micromol/kg/min. No patient was overtly septic, hypoxic, or hypovolemic. RESULTS: The infusion of glucose significantly increased the arterial glucose concentration and rate of glucose oxidation, with a corresponding increase in the arterial plasma concentration of lactate and pyruvate. Resting energy expenditure and oxygen consumption were not affected by the infusion of glucose. CONCLUSIONS: These findings show that elevations in plasma lactate in severely injured patients may, in part, be related to increases in glucose flux and not entirely a reflection of any deficit in oxygen availability. Such findings highlight a potential pitfall for interpreting plasma lactate concentrations as an index of tissue oxygen availability in hypermetabolic patients. 相似文献
82.
Donna L Forrest Donna E Hogge Thomas J Nevill Stephen H Nantel Michael J Barnett John D Shepherd Heather J Sutherland Cynthia L Toze Clayton A Smith Julye C Lavoie Kevin W Song Nicholas J Voss Randy D Gascoyne Joseph M Connors 《Journal of clinical oncology》2005,23(31):7994-8002
PURPOSE: To determine the incidence of second malignancies among patients with Hodgkin's lymphoma (HL) treated with autologous hematopoietic stem cell transplantation (AHSCT) compared with patients receiving conventional therapy alone and to identify potential risk factors for their occurrence. PATIENTS AND METHODS: We analyzed data on 1,732 consecutive patients with HL treated at the British Columbia Cancer Agency from 1976 to 2001, including 202 patients undergoing AHSCT. The median follow-up duration was 9.8 years for the whole cohort, 9.7 years for those patients treated with conventional therapy, and 7.8 years from AHSCT. RESULTS: The cumulative incidence of developing any second malignancy 15 years after therapy for HL was 9% (risk ratio = 3.5; P < .001); however, the incidence did not differ between those patients receiving conventional therapy alone compared with those undergoing AHSCT (10% and 8%, respectively; P = .48). In multivariate analysis, the only factor significantly associated with an increased risk of developing any second neoplasm or solid tumor was age > or = 35 years (P < .0001). An increased risk of therapy-induced acute myeloid leukemia and therapy-induced myelodysplastic syndrome was seen for patients aged > or = 35 years (P = .03) and stage III/IV (P = .04). CONCLUSION: Patients with HL are at increased risk of developing a second neoplasm. However, those patients undergoing AHSCT do not seem to be at greater risk compared with those patients receiving conventional therapy alone, at least during the first decade after therapy. 相似文献
83.
Desloratadine (descarboethoxyloratadine, CAS 100643-71-8) is a selective histamine H1 antagonist that exhibits qualitatively similar pharmacodynamic activity to its parent, loratadine (CAS 79794-75-5), but is 2.5-4 times more potent orally. In studies of central nervous system (CNS) effects that might lead to sedation, desloratadine had no behavioral, neurological or autonomic effects in the conscious mouse and rat. At large multiples of the antihistaminic dose in the mouse, it did not inhibit convulsions caused by electroconvulsive shock and inhibited acetic acid-induced writhing only at a dose approximately 1,000 times the antihistaminic dose in the mouse. Desloratadine had no effects on blood pressure, heart rate or electrocardiographic parameters in the rat or guinea pig or on electrocardiographic parameters in the monkey. Notably, there was no effect on the corrected Q-wave to T-wave (QTc) interval. Desloratadine did not inhibit IKr channel human ether-a-go-go-related gene (HERG)-induced current in a study in which HERG was expressed in Xenopus oocytes. In the rat, desloratadine did not cause effects in urine volume, electrolytes or creatinine, or inhibit gastric emptying or intestinal transit, or cause any harmful effects on gastric mucosa. The results of these preclinical studies provide evidence that desloratadine is a safe antihistamine without CNS or cardiovascular effects. 相似文献
84.
Barnett JC Hurd WW Rogers RM Williams NL Shapiro SA 《Journal of minimally invasive gynecology》2007,14(5):664-72; quiz 673
85.
86.
The patellofemoral joint was imaged with magnetic resonance (MR) in the axial plane while the knee was positioned from 0 degrees to 32 degrees of flexion (nine positions). These multiple sequential images obtained within the early phases of flexion of the knee were viewed in a "cine-loop" format, producing a kinematic study that clearly demonstrated the relationship of the patella to the trochlear groove. Four healthy subjects and one patient with known bilateral subluxing patellae were studied. The preliminary results suggest that kinematic MR imaging of the patellofemoral joint is potentially useful for the evaluation of patellar tracking abnormalities. 相似文献
87.
Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor 总被引:2,自引:1,他引:2
Wuillemin WA; Minnema M; Meijers JC; Roem D; Eerenberg AJ; Nuijens JH; ten Cate H; Hack CE 《Blood》1995,85(6):1517-1526
From experiments with purified proteins, it has been concluded that factor XIa (FXIa) is inhibited in plasma mainly by alpha 1-antitrypsin (a1AT), followed by antithrombin III (ATIII), C1-inhibitor (C1Inh), and alpha 2-antiplasmin (a2AP). However, the validity of this concept has never been studied in plasma. We established the relative contribution of different inhibitors to the inactivation of FXIa in human plasma, using enzyme-linked immunosorbent assays (ELISAs) for the quantification of complexes of FXIa with a1AT, C1Inh, a2AP, and ATIII. We found that 47% of FXIa added to plasma formed complexes with C1Inh, 24.5% with a2AP, 23.5% with a1AT, and 5% with ATIII. The distribution of FXIa between these inhibitors in plasma was independent of whether FXIa was added to plasma, or was activated endogenously by kaolin, celite, or glass. However, in the presence of heparin (1 or 50 U/mL), C1Inh appeared to be the major inhibitor of FXIa, followed by ATIII. Furthermore, at lower temperatures, less FXIa-C1Inh and FXIa-a1AT complexes but more FXIa-a2AP complexes were formed. These data demonstrate that the contribution of the different inhibitors to inactivation of FXIa in plasma may vary, but C1Inh is the principal inhibitor under most conditions. 相似文献
88.
89.
90.
Familial protein S deficiency with a variant protein S molecule in plasma and platelets 总被引:3,自引:0,他引:3
A protein S deficient family presenting a variant protein S molecule in plasma and platelets is described. The propositus, age 20, and two brothers suffered from venous thrombotic disease. The propositus, the only family member studied while taking oral anticoagulants, had a protein S antigen (ag) level of 17% and undetectable activity. As demonstrated by immunoblotting both the propositus and one clinically affected brother (42% ag, 7% activity) presented variant protein S molecules of 65,000 molecular weight (mol wt) while the other clinically affected brother (64% ag, 11% activity) had only protein S with normal electrophoretic mobility of 70,000 mol wt. The mother had normal protein S levels (93% ag, 100% activity) but had both normal and variant protein S molecules and based on her functional protein S data a normal anticoagulant activity of the variant molecule is suggested. One asymptomatic but protein S deficient sister (68% ag, 9% activity) as well as the asymptomatic protein S deficient father (59% ag, 10% activity) had only protein S molecules of 70,000 mol wt. The variant protein S bound to C4b-binding protein in plasma, and differed from normal protein S in carbohydrate content. Platelets of each family member contained the same immunoblotting pattern of normal and variant protein S forms as found in plasma, consistent with the hypothesis that protein S gene expression involves codominant expression of two alleles that is similar in cells that control the synthesis of both platelet and plasma forms of protein S. 相似文献